Literature DB >> 11307178

Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study.

J Ludvigsson1, U Samuelsson, C Johansson, L Stenhammar.   

Abstract

BACKGROUND: In recent years different types of immune interventions have been tried at the onset of type 1 diabetes. Although some have shown effects, none have proven to be sufficiently effective to justify the inherent risks and side effects. Antioxidants have no or minimal side effects. If they can protect the beta cells against free oxygen radicals during the inflammatory process this would be a safe and cheap intervention. To evaluate this hypothesis a combination of various antioxidative agents was employed in a double-blind randomized study.
METHODS: The study group comprised 46 children aged 1-17 years at diagnosis. They were followed for 3 years: 2 years whilst taking the tablets and 1 year of follow-up. Twenty-four children were randomly allocated to active treatment with high doses of antioxidants and 22 children to placebo tablets. The tablets were the same size and tasted identical.
RESULTS: Twenty patients had for more than 1 month an insulin dose <0.5 U/kg in parallel with a normal HbA(1c) value and stable blood glucose values, but with no difference observed between those with and without active treatment. Nor was any significant difference observed regarding C-peptide values, fasting as well as stimulated. Whilst the antioxidants demonstrated no positive effect, they also had no negative side effects.
CONCLUSION: At diagnosis of type 1 diabetes in children, high doses of antioxidative agents have no effect either on the preservation of beta cell function or on metabolic balance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11307178     DOI: 10.1002/dmrr.176

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  8 in total

1.  Immune intervention in children with type 1 diabetes.

Authors:  Johnny Ludvigsson
Journal:  Curr Diab Rep       Date:  2010-10       Impact factor: 4.810

Review 2.  The role of immunomodulation therapy in autoimmune diabetes.

Authors:  Johnny Ludvigsson
Journal:  J Diabetes Sci Technol       Date:  2009-03-01

Review 3.  Redox-Sensitive Innate Immune Pathways During Macrophage Activation in Type 1 Diabetes.

Authors:  Ashley R Burg; Hubert M Tse
Journal:  Antioxid Redox Signal       Date:  2017-11-27       Impact factor: 8.401

4.  Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.

Authors:  J Ludvigsson; M Hjorth; M Chéramy; S Axelsson; M Pihl; G Forsander; N-Ö Nilsson; B-O Samuelsson; T Wood; J Aman; E Ortqvist; R Casas
Journal:  Diabetologia       Date:  2010-11-30       Impact factor: 10.122

Review 5.  Lipid metabolism in pregnancy and its consequences in the fetus and newborn.

Authors:  Emilio Herrera
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

Review 6.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

Review 7.  Therapies to Preserve β-Cell Function in Type 1 Diabetes.

Authors:  Johnny Ludvigsson
Journal:  Drugs       Date:  2016-02       Impact factor: 11.431

8.  Frequent Monitoring of C-Peptide Levels in Newly Diagnosed Type 1 Subjects Using Dried Blood Spots Collected at Home.

Authors:  Ruben H Willemsen; Keith Burling; Peter Barker; Fran Ackland; Renuka P Dias; Julie Edge; Anne Smith; John Todd; Boryana Lopez; Adrian P Mander; Catherine Guy; David B Dunger
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.